Page 10 - Glenmark Pharmaceuticals
Glenmark's Glenn Saldanha appointed IPA President
Indian Pharmaceutical Alliance (IPA), a body of major domestic pharma firms, today said Glenn Saldanha has been appointed as President for 2017-19. Saldanha is Chairman & Managing Director of Glenmark Pharmaceuticals. IPA also appointed Panacea Biotec Joint Managing Director Rajesh Jain as Vice President. The IPA, initially formed by eight national companies in November 1999, has now 20 research-based national pharmaceutical companies in its fold. Some of the prominent members include Lupin, Cadila Healthcare, Cipla, Dr Reddy's Laboratories and Sun Pharmaceutical Industries among others.
 "Glenmark's Glenn Saldanha appointed IPA President")
Risk-reward favourable for Glenmark
Growth momentum to continue in FY18 as firm beats peers in Q1, out-licensing deal a trigger
Glenmark Pharma records 47% jump in Q1 net at Rs 333 cr
The company continues to be one of the fastest growing companies in the pharma market
 "Glenmark Pharma records 47% jump in Q1 net at Rs 333 cr")
Glenmark Pharma's generic anti-inflammatory drug gets USFDA nod
Approval is for Indomethacin extended-release capsules of 75 mg strength, the company said
 "Glenmark Pharma's generic anti-inflammatory drug gets USFDA nod")
Glenmark gets USFDA's approval to sell generic blood pressure medicine
Glenmark's tablets will be manufactured by company's manufacturing facility located in Goa
Glenmark Pharma hits 52-week low post Q4 results
The stock hit 52-week low of Rs 716, down 5.5%, extending its Friday's 16% on BSE.
Glenmark Pharma falls 16%, records biggest intra-day fall in 7 years
The stock recorded its sharpest intra-day fall since August 19, 2009
Pharma major Glenmark's Ankleshwar plant gets EIR report from USFDA
The stock was trading at Rs 905, up 1.58 per cent from its previous close on BSE
Glenmark ties up with Evestra to develop contraceptive
The companies will file for product approval in FY19
Street awaits fresh triggers for Glenmark Pharmaceuticals
Approvals to launch drugs in US, rebound in domestic growth, debt reduction key for upgrades
 "Street awaits fresh triggers for Glenmark Pharmaceuticals")
Glenmark aims for substantial debt reduction in FY 17
The firm is expecting a strong growth in its US business in the second half of the year.
 "Glenmark aims for substantial debt reduction in FY 17")
Glenmark gets US FDA nod for Xylocaine ointment
Glenmark's current portfolio consists of 109 products authorised for distribution in the US and 62 ANDA's pending approval with the US FDA
 "Glenmark gets US FDA nod for Xylocaine ointment")
Glenmark Pharmaceuticals' Q1 net profit up 24% at Rs 227 crore
The company had reported a net profit after tax, minority interest and share of profit of associates of Rs 182.94 crore
